EQL Pharma AB Reports Strong Q4 Financial Performance with Doubling of EBITDA Amidst Challenging Market Conditions
EQL Pharma AB reported a strong Q4 2024/2025 with a 28.0 million SEK increase in EBITDA, driven by revenue growth of 38.23% and a focus on targeting Nordic pharmacies and hospitals.
2 minutes to read